147 related articles for article (PubMed ID: 26260781)
1. Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid.
Tong GX; Mody K; Wang Z; Hamele-Bena D; Nikiforova MN; Nikiforov YE
Endocr Pathol; 2015 Dec; 26(4):315-9. PubMed ID: 26260781
[TBL] [Abstract][Full Text] [Related]
2. PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.
Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
Endocr Pathol; 2015 Dec; 26(4):365-9. PubMed ID: 26530486
[TBL] [Abstract][Full Text] [Related]
3. [The analysis of genetic and clinicopathologic characteristics in patients with follicular thyroid neoplasm].
Zhang J; Li Y; Lyu N; Ying JM
Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):594-598. PubMed ID: 31434450
[No Abstract] [Full Text] [Related]
4. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
[TBL] [Abstract][Full Text] [Related]
5. [Transfection of follicular thyroid gland carcinoma cells with human TSH receptor changes growth, invasion and adhesion].
Hoelting T; Duh QY; Clark OH; Herfarth C
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):281-4. PubMed ID: 14518260
[TBL] [Abstract][Full Text] [Related]
6. Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes.
Niepomniszcze H; Suárez H; Pitoia F; Pignatta A; Danilowicz K; Manavela M; Elsner B; Bruno OD
Thyroid; 2006 May; 16(5):497-503. PubMed ID: 16756473
[TBL] [Abstract][Full Text] [Related]
7. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases.
Führer D; Tannapfel A; Sabri O; Lamesch P; Paschke R
Endocr Relat Cancer; 2003 Dec; 10(4):591-600. PubMed ID: 14713269
[TBL] [Abstract][Full Text] [Related]
8. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas.
Cetani F; Tonacchera M; Pinchera A; Barsacchi R; Basolo F; Miccoli P; Pacini F
J Endocrinol Invest; 1999 Apr; 22(4):273-8. PubMed ID: 10342361
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
10. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
11. Differences in Mutational Profile between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma Identified Using Next Generation Sequencing.
Borowczyk M; Szczepanek-Parulska E; Dębicki S; Budny B; Verburg FA; Filipowicz D; Więckowska B; Janicka-Jedyńska M; Gil L; Ziemnicka K; Ruchała M
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31248021
[TBL] [Abstract][Full Text] [Related]
12. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
13. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
14. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.
Hoffmann S; Maschuw K; Hassan I; Wunderlich A; Lingelbach S; Ramaswamy A; Hofbauer LC; Zielke A
Endocrine; 2006 Aug; 30(1):129-38. PubMed ID: 17185801
[TBL] [Abstract][Full Text] [Related]
15. Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma.
Tong GX; Chang Q; Hamele-Bena D; Carew J; Hoffman RS; Nikiforova MN; Nikiforov YE
Endocr Pathol; 2016 Mar; 27(1):70-5. PubMed ID: 26744121
[TBL] [Abstract][Full Text] [Related]
16. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
17. A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism.
Camacho P; Gordon D; Chiefari E; Yong S; DeJong S; Pitale S; Russo D; Filetti S
Thyroid; 2000 Nov; 10(11):1009-12. PubMed ID: 11128715
[TBL] [Abstract][Full Text] [Related]
18. [Update on differenciated thyroid carcinoma].
Karayan L; Hadjadj S; Larsen CJ; Maréchaud R; Kraimps JL
Bull Cancer; 2002 Jan; 89(1):113-23. PubMed ID: 11847033
[TBL] [Abstract][Full Text] [Related]
19. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
